This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Androgen receptor; FK506 binding protein 4 (FKBP4); prostate-specific antigen (KLK3; PSA)	Cell culture studies identified compounds that block FKBP4–androgen receptor interactions and could help treat prostate cancer. In cell culture, a lead compound inhibited androgen receptor signaling at low micromolar concentrations. In cultured prostate cancer cells, the compound lowered PSA concentrations and inhibited androgen-dependent prostate cell proliferation compared with vehicle. Next steps include optimizing molecules for potency and solubility and testing them *in vivo*. ***SciBX*** **4(28); doi:10.1038/scibx.2011.792** **Published online July 21, 2011**	Patent applications filed; available for licensing from the NIH **Contact:** Sabarni Chatterjee, NIH Office of Technology Transfer, Rockville, Md. e-mail: chatterjeesa@mail.nih.gov	De Leon, J.T. *et al.* *Proc. Natl. Acad. Sci. USA*; published online July 5, 2011; doi:10.1073/pnas.1105160108 **Contact:** Marc B. Cox, The University of Texas at El Paso, El Paso, Texas e-mail: mbcox@utep.edu